Jeffrey Dierks - Mar 15, 2024 Form 4 Insider Report for Harmony Biosciences Holdings, Inc. (HRMY)

Role
CHIEF COMMERCIAL OFFICER
Signature
/s/ Christian Ulrich, Attorney-in-Fact
Stock symbol
HRMY
Transactions as of
Mar 15, 2024
Transactions value $
-$284,861
Form type
4
Date filed
3/18/2024, 07:24 PM
Previous filing
Mar 11, 2024
Next filing
Sep 30, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRMY Common Stock Options Exercise $98.5K +12K $8.22 12K Mar 15, 2024 Direct
transaction HRMY Common Stock Sale -$383K -12K -100% $32.00 0 Mar 15, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HRMY Stock Option Options Exercise $0 -2.34K -100% $0.00* 0 Mar 15, 2024 Common Stock 2.34K $8.22 Direct F3
transaction HRMY Stock Option Options Exercise $0 -9.64K -66.45% $0.00 4.87K Mar 15, 2024 Common Stock 9.64K $8.22 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.06. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The stock option vests in five equal annual installments beginning on October 1, 2019.
F4 The stock option vests in five equal annual installments beginning on March 1, 2021.